MindMed annual meeting adjourned; potential Nasdaq delisting risk from quorum issue

Definium Therapeutics, Inc.

2023 annual general meeting on June 15 failed due to lack of 33 1/3% quorum; reconvened for June 21 at 10 a.m. ET.
Articles allow meeting to proceed with whatever persons present if quorum not met within 30 minutes of reconvened meeting.
Nasdaq may issue non-compliance letter if less than 33 1/3% present; company has 45 days to submit plan, possible 180-day extension.
Potential delisting would negatively impact liquidity and market price; company believes it can regain compliance but no assurance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.